Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A

Blood

Volumn 125, Issue 24, 2015, Pages 3747-3755

  Zonta, Francesca ^a   Pagano, Mario Angelo ^a   Trentin, Livio ^a,b   Tibaldi, Elena ^a   Frezzato, Federica ^a,b   Trimarco, Valentina ^a,b   Facco, Monica ^a,b   Zagotto, Giuseppe ^a   Pavan, Valeria ^a   Ribaudo, Giovanni ^a   Bordin, Luciana ^a   Semenzato, Gianpietro ^a,b   Brunati, Anna Maria ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; DASATINIB; FINGOLIMOD; GELDANAMYCIN; MP 07 66; OKADAIC ACID; PHOSPHATASE INHIBITOR COCKTAIL; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOTYROSINE; PROTEIN KINASE LYN; PROTEIN TYROSINE KINASE INHIBITOR; SARACATINIB; THREONINE; UNCLASSIFIED DRUG; CHAPERONE; HEAT SHOCK PROTEIN 90; IMMUNOSUPPRESSIVE AGENT; LYN PROTEIN-TYROSINE KINASE; PHOSPHOPROTEIN PHOSPHATASE 2; PROPANEDIOL DERIVATIVE; PROTEIN TYROSINE KINASE; SET PROTEIN, HUMAN; SPHINGOSINE; TRANSCRIPTION FACTOR;

APOPTOSIS; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; CHEMISTRY; DRUG EFFECTS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

APOPTOSIS; HISTONE CHAPERONES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PHOSPHORYLATION; PHOSPHOTYROSINE; PROPYLENE GLYCOLS; PROTEIN INTERACTION MAPS; PROTEIN PHOSPHATASE 2; SIGNAL TRANSDUCTION; SPHINGOSINE; SRC-FAMILY KINASES; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 84931275299     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-12-619155     Document Type: Article

References (56)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352(8):804-815.
2. Caligaris-Cappio F, Ghia P. Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J Clin Oncol. 2008;26(27):4497-4503.
3. Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet. 2008;371(9617):1017-1029.
4. Pascutti MF, Jak M, Tromp JM, et al. IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. Blood. 2013;122(17):3010-3019.
5. Arvaniti E, Ntoufa S, Papakonstantinou N, et al. Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients. Haematologica. 2011;96(11):1644-1652.
6. Oppezzo P, Dighiero G. "Role of the B-cell receptor and the microenvironment in chronic lymphocytic leukemia". Blood Cancer J. 2013;3:e149.
7. ten Hacken E, Burger JA. Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies. Pharmacol Ther. 2014;144(3):338-348.
8. Byrd JC, Brown JR, O'Brien S, et al RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213-223.
9. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997-1007.
10. Garber K. Kinase inhibitors overachieve in CLL. Nat Rev Drug Discov. 2014;13(3):162-164.
11. Contri A, Brunati AM, Trentin L, et al. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest. 2005;115(2):369-378.
12. Trentin L, Frasson M, Donella-Deana A, et al. Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia. Blood. 2008;112(12):4665-4674.
13. Zonta F, Pagano MA, Trentin L, et al. Lyn-mediated procaspase 8 dimerization blocks apoptotic signaling in B-cell chronic lymphocytic leukemia. Blood. 2014;123(6):875-883.
14. McCormack PL, Keam SJ. Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia. Drugs. 2011;71(13):1771-1795.
15. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol. 2014;89(5):547-556.
16. McCaig AM, Cosimo E, Leach MT, Michie AM. Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals. Br J Haematol. 2011;153(2):199-211.
17. Amrein PC, Attar EC, Takvorian T, et al. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2011;17(9):2977-2986.
18. Kater AP, Spiering M, Liu RD, et al. Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study. Leuk Res. 2014;38(1):34-41.
19. Nagao T, Takahashi N, Kameoka Y, et al. Dasatinib-responsive chronic lymphocytic leukemia in a patient treated for coexisting chronic myeloid leukemia. Intern Med. 2013;52(22):2567-2571.
20. McCaig AM, Cosimo E, Leach MT, Michie AM. Dasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12. PLoS ONE. 2012;7(11):e48929.
21. Mumby M. PP2A: unveiling a reluctant tumor suppressor. Cell. 2007;130(1):21-24.
22. Switzer CH, Cheng RY, Vitek TM, Christensen DJ, Wink DA, Vitek MP. Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene. 2011;30(22):2504-2513.
23. Christensen DJ, Chen Y, Oddo J, et al. SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target. Blood. 2011;118(15):4150-4158.
24. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990-4997.
25. Trentin L, Perin A, Siviero M, et al. B7 costimulatory molecules from malignant cells in patients with b-cell chronic lymphoproliferative disorders trigger t-cell proliferation. Cancer. 2000;89(6):1259-1268.
26. Cerutti A, Trentin L, Zambello R, et al. The CD5/CD72 receptor system is coexpressed with several functionally relevant counterstructures on human B cells and delivers a critical signaling activity. J Immunol. 1996;157(5):1854-1862.
27. Frezzato F, Trimarco V, Martini V, et al. Leukaemic cells from chronic lymphocytic leukaemia patients undergo apoptosis following microtubule depolymerization and Lyn inhibition by nocodazole. Br J Haematol. 2014;165(5):659-672.
28. Gamliel A, Afri M, Frimer AA. Determining radical penetration of lipid bilayers with new lipophilic spin traps. Free Radic Biol Med. 2008;44(7):1394-1405.
29. Masuzawa Y, Kudou T, Maizuru Y, et al. Preparation of haloalkylsulfonanilide derivatives as herbicides. WO 2008/102908 A1, 2008 Aug 28.
30. Rothschild SI, Gautschi O, Haura EB, Johnson FM. Src inhibitors in lung cancer: current status and future directions. Clin Lung Cancer. 2010;11(4):238-242.
31. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 2005;9(1):59-71.
32. Mishra R. Glycogen synthase kinase 3 beta: can it be a target for oral cancer. Mol Cancer. 2010;9:144.
33. Tibaldi E, Brunati AM, Zonta F, et al. Lyn-mediated SHP-1 recruitment to CD5 contributes to resistance to apoptosis of B-cell chronic lymphocytic leukemia cells. Leukemia. 2011;25(11):1768-1781.
34. Fernández JJ, Candenas ML, Souto ML, Trujillo MM, Norte M. Okadaic acid, useful tool for studying cellular processes. Curr Med Chem. 2002;9(2):229-262.
35. Swingle M, Ni L, Honkanen RE. Small-molecule inhibitors of ser/thr protein phosphatases: specificity, use and common forms of abuse. Methods Mol Biol. 2007;365:23-38.
36. Chen J, Martin BL, Brautigan DL. Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. Science. 1992;257(5074):1261-1264.
37. Seshacharyulu P, Pandey P, Datta K, Batra SK. Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Lett. 2013;335(1):9-18.
38. Chen W, Wang Z, Jiang C, Ding Y. PP2A-mediated anticancer therapy. Gastroenterol Res Pract. 2013;2013:675429.
39. Perrotti D, Neviani P. Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol. 2013;14(6):e229-e238.
40. Huyer G, Liu S, Kelly J, et al. Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate. J Biol Chem. 1997;272(2):843-851.
41. Pelletier D, Hafler DA. Fingolimod for multiple sclerosis. N Engl J Med. 2012;366(4):339-347.
42. Pitman MR, Woodcock JM, Lopez AF, Pitson SM. Molecular targets of FTY720 (fingolimod). Curr Mol Med. 2012;12(10):1207-1219.
43. Cyster JG, Schwab SR. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu Rev Immunol. 2012;30:69-94.
44. Saddoughi SA, Gencer S, Peterson YK, et al. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med. 2013;5(1):105-121.
45. Mani R, Mao Y, Frissora FW, et al. Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B cell cytotoxicity in chronic lymphocytic leukemia. Leukemia. 2015;29(2):346-355.
46. Omar HA, Chou CC, Berman-Booty LD, et al. Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma. Hepatology. 2011;53(6):1943-1958.
47. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004;427(6972):355-360.
48. Brunati AM, Tibaldi E, Carraro A, et al. Cross-talk between PDGF and S1P signalling elucidates the inhibitory effect and potential antifibrotic action of the immunomodulator FTY720 in activated HSC-cultures. Biochim Biophys Acta. 2008;1783(3):347-359.
49. Liu Q, Zhao X, Frissora F, et al. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood. 2008;111(1):275-284.
50. Billard C. Design of novel BH3 mimetics for the treatment of chronic lymphocytic leukemia. Leukemia. 2012;26(9):2032-2038.
51. Thomas LW, Lam C, Edwards SW. Mcl-1; the molecular regulation of protein function. FEBS Lett. 2010;584(14):2981-2989.
52. Samanta AK, Chakraborty SN, Wang Y, et al. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene. 2009;28(14):1669-1681.
53. Oaks JJ, Santhanam R, Walker CJ, et al. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood. 2013;122(11):1923-1934.
54. Pippa R, Dominguez A, Christensen DJ, et al. Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity. Leukemia. 2014;28(9):1915-1918.
55. Cristóbal I, Garcia-Orti L, Cirauqui C, et al. Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. Haematologica. 2012;97(4):543-550.
56. Agarwal A, MacKenzie RJ, Pippa R, et al. Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clin Cancer Res. 2014;20(8):2092-2103.